On January 15, 2025 Bectas Therapeutics will present an overview of their precision immunotherapy programs at The Biotech Showcase in San Francisco. This overview will include Bectas’ first-in-class antibody programs that focus on myeloid checkpoints in cancer and autoimmunity and that are enabled by patient selection biomarkers.